Company profile
Vigil Neuroscience company profile
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.
Business identity
- Website
- https://www.vigilneuro.com
- Contact email
- [email protected]
- Phone number
- 857-254-4445
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 51-100 employees
- Revenue range
- $0+
- Founded
- 2020-01-01, Year
Headquarters
- Headquarters
- Primghar, Iowa, United States
- Postal code
- 02139
- Country code
- US
- Continent
- North America